 | • レポートコード：MRC2Q12-18850 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、76ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、メシル酸アパチニブのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 メシル酸アパチニブのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 メシル酸アパチニブの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 メシル酸アパチニブのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのメシル酸アパチニブの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のメシル酸アパチニブの売上および2028年までの予測に焦点を当てています。 メシル酸アパチニブのグローバル主要企業には、Fuslai、Tianyu Pharma、Hengruiなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 メシル酸アパチニブ市場は、タイプとアプリケーションによって区分されます。世界のメシル酸アパチニブ市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 0.375G、0.425G 【アプリケーション別セグメント】 進行胃腺癌、胃食道接合部腺癌 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - メシル酸アパチニブ製品概要 - タイプ別市場（0.375G、0.425G） - アプリケーション別市場（進行胃腺癌、胃食道接合部腺癌） - 調査の目的 ・エグゼクティブサマリー - 世界のメシル酸アパチニブ販売量予測2017-2028 - 世界のメシル酸アパチニブ売上予測2017-2028 - メシル酸アパチニブの地域別販売量 - メシル酸アパチニブの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別メシル酸アパチニブ販売量 - 主要メーカー別メシル酸アパチニブ売上 - 主要メーカー別メシル酸アパチニブ価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（0.375G、0.425G） - メシル酸アパチニブのタイプ別販売量 - メシル酸アパチニブのタイプ別売上 - メシル酸アパチニブのタイプ別価格 ・アプリケーション別市場規模（進行胃腺癌、胃食道接合部腺癌） - メシル酸アパチニブのアプリケーション別販売量 - メシル酸アパチニブのアプリケーション別売上 - メシル酸アパチニブのアプリケーション別価格 ・北米市場 - 北米のメシル酸アパチニブ市場規模（タイプ別、アプリケーション別） - 主要国別のメシル酸アパチニブ市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのメシル酸アパチニブ市場規模（タイプ別、アプリケーション別） - 主要国別のメシル酸アパチニブ市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のメシル酸アパチニブ市場規模（タイプ別、アプリケーション別） - 主要国別のメシル酸アパチニブ市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のメシル酸アパチニブ市場規模（タイプ別、アプリケーション別） - 主要国別のメシル酸アパチニブ市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのメシル酸アパチニブ市場規模（タイプ別、アプリケーション別） - 主要国別のメシル酸アパチニブ市場規模（トルコ、サウジアラビア） ・企業情報 Fuslai、Tianyu Pharma、Hengrui ・産業チェーン及び販売チャネル分析 - メシル酸アパチニブの産業チェーン分析 - メシル酸アパチニブの原材料 - メシル酸アパチニブの生産プロセス - メシル酸アパチニブの販売及びマーケティング - メシル酸アパチニブの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - メシル酸アパチニブの産業動向 - メシル酸アパチニブのマーケットドライバー - メシル酸アパチニブの課題 - メシル酸アパチニブの阻害要因 ・主な調査結果 |
Drugs for the treatment of third-line or above patients with advanced gastric adenocarcinoma or gastric-esophageal junction adenocarcinoma
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Apatinib Mesylate is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Apatinib Mesylate is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Apatinib Mesylate is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Apatinib Mesylate include Fuslai, Tianyu Pharma and Hengrui, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Apatinib Mesylate manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Apatinib Mesylate market. Further, it explains the major drivers and regional dynamics of the global Apatinib Mesylate market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Fuslai
Tianyu Pharma
Hengrui
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by dosage strength and by application segments based on sales, price, and value for the period 2017-2028.
Apatinib Mesylate Segment by Dosage Strength
0.375G
0.425G
Apatinib Mesylate Segment by Application
Advanced Gastric Adenocarcinoma
Gastric-esophageal Junction Adenocarcinoma
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Apatinib Mesylate market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Apatinib Mesylate, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Apatinib Mesylate, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Apatinib Mesylate, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Apatinib Mesylate sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Apatinib Mesylate market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Apatinib Mesylate sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Fuslai, Tianyu Pharma and Hengrui, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Apatinib Mesylate in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Apatinib Mesylate manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Apatinib Mesylate sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Apatinib Mesylate Product Introduction
1.2 Market by Dosage Strength
1.2.1 Global Apatinib Mesylate Market Size Growth Rate by Dosage Strength, 2017 VS 2021 VS 2028
1.2.2 0.375G
1.2.3 0.425G
1.3 Market by Application
1.3.1 Global Apatinib Mesylate Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Advanced Gastric Adenocarcinoma
1.3.3 Gastric-esophageal Junction Adenocarcinoma
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Apatinib Mesylate Sales Estimates and Forecasts 2017-2028
2.2 Global Apatinib Mesylate Revenue Estimates and Forecasts 2017-2028
2.3 Global Apatinib Mesylate Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Apatinib Mesylate Sales by Region
2.4.1 Global Apatinib Mesylate Sales by Region (2017-2022)
2.4.2 Global Sales Apatinib Mesylate by Region (2023-2028)
2.5 Global Apatinib Mesylate Revenue by Region
2.5.1 Global Apatinib Mesylate Revenue by Region (2017-2022)
2.5.2 Global Apatinib Mesylate Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Apatinib Mesylate Sales by Manufacturers
3.1.1 Global Top Apatinib Mesylate Manufacturers by Sales (2017-2022)
3.1.2 Global Apatinib Mesylate Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Apatinib Mesylate in 2021
3.2 Global Apatinib Mesylate Revenue by Manufacturers
3.2.1 Global Apatinib Mesylate Revenue by Manufacturers (2017-2022)
3.2.2 Global Apatinib Mesylate Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Apatinib Mesylate Revenue in 2021
3.3 Global Apatinib Mesylate Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Apatinib Mesylate Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Apatinib Mesylate Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Dosage Strength
4.1 Global Apatinib Mesylate Sales by Dosage Strength
4.1.1 Global Apatinib Mesylate Historical Sales by Dosage Strength (2017-2022)
4.1.2 Global Apatinib Mesylate Forecasted Sales by Dosage Strength (2023-2028)
4.1.3 Global Apatinib Mesylate Sales Market Share by Dosage Strength (2017-2028)
4.2 Global Apatinib Mesylate Revenue by Dosage Strength
4.2.1 Global Apatinib Mesylate Historical Revenue by Dosage Strength (2017-2022)
4.2.2 Global Apatinib Mesylate Forecasted Revenue by Dosage Strength (2023-2028)
4.2.3 Global Apatinib Mesylate Revenue Market Share by Dosage Strength (2017-2028)
4.3 Global Apatinib Mesylate Price by Dosage Strength
4.3.1 Global Apatinib Mesylate Price by Dosage Strength (2017-2022)
4.3.2 Global Apatinib Mesylate Price Forecast by Dosage Strength (2023-2028)
5 Market Size by Application
5.1 Global Apatinib Mesylate Sales by Application
5.1.1 Global Apatinib Mesylate Historical Sales by Application (2017-2022)
5.1.2 Global Apatinib Mesylate Forecasted Sales by Application (2023-2028)
5.1.3 Global Apatinib Mesylate Sales Market Share by Application (2017-2028)
5.2 Global Apatinib Mesylate Revenue by Application
5.2.1 Global Apatinib Mesylate Historical Revenue by Application (2017-2022)
5.2.2 Global Apatinib Mesylate Forecasted Revenue by Application (2023-2028)
5.2.3 Global Apatinib Mesylate Revenue Market Share by Application (2017-2028)
5.3 Global Apatinib Mesylate Price by Application
5.3.1 Global Apatinib Mesylate Price by Application (2017-2022)
5.3.2 Global Apatinib Mesylate Price Forecast by Application (2023-2028)
6 North America
6.1 North America Apatinib Mesylate Market Size by Dosage Strength
6.1.1 North America Apatinib Mesylate Sales by Dosage Strength (2017-2028)
6.1.2 North America Apatinib Mesylate Revenue by Dosage Strength (2017-2028)
6.2 North America Apatinib Mesylate Market Size by Application
6.2.1 North America Apatinib Mesylate Sales by Application (2017-2028)
6.2.2 North America Apatinib Mesylate Revenue by Application (2017-2028)
6.3 North America Apatinib Mesylate Market Size by Country
6.3.1 North America Apatinib Mesylate Sales by Country (2017-2028)
6.3.2 North America Apatinib Mesylate Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Apatinib Mesylate Market Size by Dosage Strength
7.1.1 Europe Apatinib Mesylate Sales by Dosage Strength (2017-2028)
7.1.2 Europe Apatinib Mesylate Revenue by Dosage Strength (2017-2028)
7.2 Europe Apatinib Mesylate Market Size by Application
7.2.1 Europe Apatinib Mesylate Sales by Application (2017-2028)
7.2.2 Europe Apatinib Mesylate Revenue by Application (2017-2028)
7.3 Europe Apatinib Mesylate Market Size by Country
7.3.1 Europe Apatinib Mesylate Sales by Country (2017-2028)
7.3.2 Europe Apatinib Mesylate Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Apatinib Mesylate Market Size by Dosage Strength
8.1.1 Asia Pacific Apatinib Mesylate Sales by Dosage Strength (2017-2028)
8.1.2 Asia Pacific Apatinib Mesylate Revenue by Dosage Strength (2017-2028)
8.2 Asia Pacific Apatinib Mesylate Market Size by Application
8.2.1 Asia Pacific Apatinib Mesylate Sales by Application (2017-2028)
8.2.2 Asia Pacific Apatinib Mesylate Revenue by Application (2017-2028)
8.3 Asia Pacific Apatinib Mesylate Market Size by Region
8.3.1 Asia Pacific Apatinib Mesylate Sales by Region (2017-2028)
8.3.2 Asia Pacific Apatinib Mesylate Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Apatinib Mesylate Market Size by Dosage Strength
9.1.1 Latin America Apatinib Mesylate Sales by Dosage Strength (2017-2028)
9.1.2 Latin America Apatinib Mesylate Revenue by Dosage Strength (2017-2028)
9.2 Latin America Apatinib Mesylate Market Size by Application
9.2.1 Latin America Apatinib Mesylate Sales by Application (2017-2028)
9.2.2 Latin America Apatinib Mesylate Revenue by Application (2017-2028)
9.3 Latin America Apatinib Mesylate Market Size by Country
9.3.1 Latin America Apatinib Mesylate Sales by Country (2017-2028)
9.3.2 Latin America Apatinib Mesylate Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Apatinib Mesylate Market Size by Dosage Strength
10.1.1 Middle East and Africa Apatinib Mesylate Sales by Dosage Strength (2017-2028)
10.1.2 Middle East and Africa Apatinib Mesylate Revenue by Dosage Strength (2017-2028)
10.2 Middle East and Africa Apatinib Mesylate Market Size by Application
10.2.1 Middle East and Africa Apatinib Mesylate Sales by Application (2017-2028)
10.2.2 Middle East and Africa Apatinib Mesylate Revenue by Application (2017-2028)
10.3 Middle East and Africa Apatinib Mesylate Market Size by Country
10.3.1 Middle East and Africa Apatinib Mesylate Sales by Country (2017-2028)
10.3.2 Middle East and Africa Apatinib Mesylate Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Fuslai
11.1.1 Fuslai Corporation Information
11.1.2 Fuslai Overview
11.1.3 Fuslai Apatinib Mesylate Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Fuslai Apatinib Mesylate Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Fuslai Recent Developments
11.2 Tianyu Pharma
11.2.1 Tianyu Pharma Corporation Information
11.2.2 Tianyu Pharma Overview
11.2.3 Tianyu Pharma Apatinib Mesylate Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Tianyu Pharma Apatinib Mesylate Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Tianyu Pharma Recent Developments
11.3 Hengrui
11.3.1 Hengrui Corporation Information
11.3.2 Hengrui Overview
11.3.3 Hengrui Apatinib Mesylate Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Hengrui Apatinib Mesylate Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Hengrui Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Apatinib Mesylate Industry Chain Analysis
12.2 Apatinib Mesylate Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Apatinib Mesylate Production Mode & Process
12.4 Apatinib Mesylate Sales and Marketing
12.4.1 Apatinib Mesylate Sales Channels
12.4.2 Apatinib Mesylate Distributors
12.5 Apatinib Mesylate Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Apatinib Mesylate Industry Trends
13.2 Apatinib Mesylate Market Drivers
13.3 Apatinib Mesylate Market Challenges
13.4 Apatinib Mesylate Market Restraints
14 Key Findings in The Global Apatinib Mesylate Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer